Analysts have been eager to weigh in on the Healthcare sector with new ratings on Jazz Pharmaceuticals (NASDAQ:JAZZ), Halozyme (NASDAQ:HALO) and Alder Biopharmaceuticals (NASDAQ:ALDR).
Jazz Pharmaceuticals (JAZZ)
In a report released today, Gary Nachman from BMO Capital maintained a Buy rating on Jazz Pharmaceuticals, with a price target of $206. The company’s shares closed yesterday at $179.90, close to its 52-week high of $184.
According to TipRanks.com, Nachman is a 4-star analyst with an average return of 11.9% and a 57.0% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Sienna Biopharmaceuticals Inc, Bausch Health Companies Inc, and Pacira Pharmaceuticals.
Currently, the analyst consensus on Jazz Pharmaceuticals is a Strong Buy with an average price target of $200.91, which is an 11.7% upside from current levels. In a report issued on July 24, Piper Jaffray also reiterated a Buy rating on the stock with a $210 price target.
.
See today’s analyst top recommended stocks >>
Halozyme (HALO)
In a report released today, Do Kim from BMO Capital maintained a Hold rating on Halozyme, with a price target of $21. The company’s shares closed yesterday at $17.62.
According to TipRanks.com, Kim is a 4-star analyst with an average return of 20.6% and a 55.7% success rate. Kim covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Akcea Therapeutics Inc, and Alnylam Pharma.
Currently, the analyst consensus on Halozyme is a Hold with an average price target of $20.
Alder Biopharmaceuticals (ALDR)
BMO Capital analyst Matthew Luchini maintained a Buy rating on Alder Biopharmaceuticals today and set a price target of $23. The company’s shares closed yesterday at $19.40, close to its 52-week high of $20.
According to TipRanks.com, Luchini ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.6% and a 35.3% success rate. Luchini covers the Healthcare sector, focusing on stocks such as Aeglea Biotherapeutics Inc, Audentes Therapeutics, and Armo Biosciences Inc.
Alder Biopharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $25.33, implying a 30.6% upside from current levels. In a report issued on August 6, Piper Jaffray also initiated coverage with a Buy rating on the stock with a $28 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
